Profession Calculators
Pharmacy & Clinical PharmacologyPopular

Drug Interaction Severity Reference

Lexi-Interact severity classification reference (Risk Ratings A through X) with common high-risk drug interactions, clinical significance, and management recommendations for pharmacy practice.

Share:

Lexi-Interact Severity Classification Reference

This reference guide provides common drug interaction examples classified by Lexicomp severity ratings. For comprehensive interaction checking, use clinical decision support software (Lexicomp, Micromedex, Clinical Pharmacology). This is not a substitute for professional interaction screening tools.

Severity Classification System
Risk Rating ANo Known Interaction

Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions.

Risk Rating BNo Action Needed

Interaction is unlikely, of limited clinical significance, or management is not typically needed.

Risk Rating CMonitor Therapy

Monitor patients for signs/symptoms of interaction. Dose adjustments may be needed but are not required in most cases.

Risk Rating DConsider Alternative

Assess risk/benefit ratio. Use alternative agents when possible. If used together, dose adjustment or close monitoring required.

Risk Rating XAvoid Combination

Risk of interaction outweighs benefit. Combination is contraindicated. Do not use together.

Common Drug Interactions Reference

warfarin + nsaid

NSAIDs increase bleeding risk when combined with warfarin

D

Severity: Major - Consider Alternative

Clinical Significance:

NSAIDs inhibit platelet function and may cause GI bleeding. Combined with warfarin, this significantly increases hemorrhage risk. INR may also increase.

Management:

Avoid combination if possible. If necessary, use lowest NSAID dose for shortest duration, monitor INR closely, and assess for bleeding signs.

simvastatin + clarithromycin

Clarithromycin significantly increases simvastatin levels, causing severe myopathy risk

X

Severity: Contraindicated - Do Not Use

Clinical Significance:

CYP3A4 inhibition by clarithromycin increases simvastatin exposure up to 10-fold, greatly increasing rhabdomyolysis risk.

Management:

Contraindicated. Discontinue simvastatin during clarithromycin therapy or use alternative antibiotic (e.g., azithromycin) or statin (e.g., pravastatin).

lisinopril + potassium

ACE inhibitors combined with potassium supplements increase hyperkalemia risk

C

Severity: Moderate - Monitor Closely

Clinical Significance:

Both agents increase serum potassium. Combined use may result in clinically significant hyperkalemia, especially in patients with renal impairment.

Management:

Monitor serum potassium regularly. Use potassium supplements cautiously and only if clearly needed. Consider dietary potassium instead.

metformin + contrast

Iodinated contrast with metformin increases lactic acidosis risk

D

Severity: Major - Consider Alternative

Clinical Significance:

Contrast-induced nephropathy may impair metformin clearance, leading to accumulation and potentially fatal lactic acidosis.

Management:

Discontinue metformin at time of or before contrast procedure in patients with eGFR 30-60. Restart 48 hours after if renal function stable.

fluconazole + warfarin

Fluconazole inhibits warfarin metabolism, significantly increasing INR

D

Severity: Major - Consider Alternative

Clinical Significance:

CYP2C9 inhibition by fluconazole increases warfarin exposure, often doubling INR within 3-5 days. Severe bleeding risk.

Management:

Reduce warfarin dose by 25-50% when starting fluconazole. Monitor INR closely (after 3-4 days, then weekly). Resume usual dose after fluconazole discontinued.

methotrexate + trimethoprim

Both agents cause folate antagonism, increasing bone marrow suppression

D

Severity: Major - Consider Alternative

Clinical Significance:

Additive folate antagonism increases risk of severe pancytopenia, mucositis, and hepatotoxicity.

Management:

Avoid combination. If unavoidable, reduce methotrexate dose, provide leucovorin rescue, and monitor CBC closely.

digoxin + amiodarone

Amiodarone increases digoxin levels and enhances AV block risk

D

Severity: Major - Consider Alternative

Clinical Significance:

P-glycoprotein inhibition by amiodarone doubles digoxin levels. Both drugs slow AV conduction, increasing bradycardia risk.

Management:

Reduce digoxin dose by 50% when starting amiodarone. Monitor digoxin levels after 1 week. Check ECG for bradycardia.

ssri + tramadol

Combined use increases serotonin syndrome and seizure risk

C

Severity: Moderate - Monitor Closely

Clinical Significance:

Additive serotonergic effects may precipitate serotonin syndrome. Both agents also lower seizure threshold.

Management:

Use combination cautiously. Educate patient on serotonin syndrome symptoms. Monitor for tremor, agitation, confusion, hyperthermia.

Important Disclaimer

This is a reference guide showing common examples only. Comprehensive interaction screening requires clinical decision support software that evaluates the complete medication list, doses, and patient-specific factors. Always use FDA-approved interaction checking tools (Lexicomp, Micromedex, First Databank) before dispensing medications. This tool is for educational purposes and must not be used as a substitute for professional drug interaction screening.

Additional High-Risk Interaction Classes

QTc Prolongation (Risk Rating D or X)

Multiple QT-prolonging agents: antipsychotics + azole antifungals, macrolides + class III antiarrhythmics, ondansetron + fluoroquinolones. Monitor ECG and electrolytes.

Serotonin Syndrome (Risk Rating C-D)

SSRI + MAOI (X), SSRI + tramadol (C), SSRI + linezolid (D), SSRI + triptans (C). Watch for agitation, tremor, hyperthermia, hyperreflexia.

Nephrotoxicity (Risk Rating C-D)

NSAID + ACE inhibitor + diuretic (triple whammy), aminoglycoside + vancomycin, NSAID + lithium. Monitor renal function and drug levels.

Anticoagulation Enhancement (Risk Rating D)

Warfarin + antibiotics (especially fluoroquinolones, metronidazole, TMP-SMX), warfarin + antifungals, DOACs + strong CYP3A4 inhibitors. Monitor INR or anti-Xa levels.

CNS Depression (Risk Rating C-D)

Opioid + benzodiazepine (D), opioid + gabapentinoid (D), multiple sedatives. Assess for respiratory depression, avoid if possible.

Embed This Calculator on Your Website

Add this free calculator to your blog, website, or CMS with a simple copy-paste embed code.

Introduction

This Drug Interaction Checker is designed for professionals who need accurate and reliable calculations in their daily work. Whether you are planning finances, managing projects, or making critical business decisions, having the right numbers at your fingertips is essential. This tool provides instant results based on proven formulas, saving you time and reducing the risk of manual calculation errors. By using this calculator, you can focus on analysis and decision-making rather than spending time on complex computations. The interface is straightforward and designed for practical use, ensuring that you get the information you need quickly and efficiently.

What This Calculator Does

This drug interaction severity reference tool provides pharmacists and healthcare providers with a quick guide to the Lexicomp drug interaction severity classification system (Risk Ratings A through X) and examples of common clinically significant drug interactions organized by severity level. The tool includes interaction mechanism, clinical significance, and evidence-based management recommendations. This is a reference guide for educational purposes and clinical awareness, not a comprehensive interaction screening database.

The Formula

This is a reference tool. Drug interaction severity is classified by clinical significance, not a mathematical formula.

Lexicomp (and other interaction databases like Micromedex, First Databank) categorize drug interactions into five severity levels. Risk Rating A indicates no known interaction. Risk Rating B indicates interactions of limited clinical significance requiring no action. Risk Rating C indicates moderate interactions requiring monitoring. Risk Rating D indicates major interactions where an alternative agent should be considered. Risk Rating X indicates contraindicated combinations that should be avoided. Severity is determined by the interaction mechanism (pharmacokinetic or pharmacodynamic), magnitude of effect, clinical consequences (bleeding, toxicity, therapeutic failure), and availability of safer alternatives.

Step-by-Step Example

1

Select or search for drug combination

Patient on warfarin presents with UTI. Physician wants to prescribe ciprofloxacin.

2

Review interaction severity

Warfarin + ciprofloxacin: Risk Rating D. Major interaction. Ciprofloxacin inhibits CYP1A2 and CYP3A4, increasing warfarin levels and INR.

3

Assess clinical significance

Combination significantly increases bleeding risk. INR may increase by 50% to 100% within 3 to 5 days of starting ciprofloxacin.

4

Implement management strategy

Consider alternative: use nitrofurantoin or cephalexin for UTI. If ciprofloxacin necessary, reduce warfarin dose by 25% to 33%, check INR after 3 days, and monitor for bleeding.

Real-World Use Cases

Medication Reconciliation

Clinical pharmacists review newly admitted patient medication lists for significant drug interactions flagged by electronic health record systems and intervene to prevent adverse events.

Discharge Counseling

Retail pharmacists identify interactions when dispensing new prescriptions and contact prescribers to recommend safer alternatives or provide patient counseling on monitoring and side effect recognition.

Student and Resident Training

Pharmacy students and residents study high-yield drug interactions by severity category to prepare for board exams and develop clinical decision-making skills for patient care rotations.

Common Mistakes to Avoid

  • Treating all drug interaction alerts equally. Most EHR systems generate dozens of low-severity alerts daily. Focus clinical time on Risk Rating D and X interactions that truly require intervention.

  • Not distinguishing between theoretical interactions and clinically documented interactions. Some interactions are based on in vitro data or case reports but lack robust clinical evidence of harm.

  • Ignoring patient-specific risk factors. An interaction that is Risk Rating C (monitor) in most patients may be Risk Rating D or X in patients with renal failure, liver disease, or multiple comorbidities.

  • Failing to communicate interaction management to the patient and other providers. Document interaction, intervention, and rationale in the medical record and notify the prescriber and patient.

Frequently Asked Questions

Accuracy and Disclaimer

This reference tool provides examples of common drug interactions for educational purposes. It is not a comprehensive drug interaction screening database and must not be used as a substitute for FDA-approved clinical decision support software (Lexicomp, Micromedex, First Databank). Comprehensive interaction screening requires evaluation of the complete medication list including prescription drugs, over-the-counter medications, supplements, and herbal products. Always use professional interaction checking tools before dispensing medications. This is not medical or pharmaceutical advice.

Conclusion

This calculator provides a reliable way to perform essential calculations for your professional needs. The results are based on standard formulas and should be used as estimates for planning and analysis purposes. For critical decisions, especially those involving financial, legal, or medical matters, it is always advisable to verify results with a qualified professional. Use this tool as part of your broader decision-making process, and explore related calculators on this platform to support your comprehensive planning needs. Regular use of accurate calculation tools helps ensure consistency and precision in your professional work.